Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

Manuela Schmidinger *

Medical University of Vienna, Vienna, Austria

1. Introduction

Vascular-endothelial growth-factor (receptor) (VEGF)(R)-inhibiting agents – sunitinib [1–3], sorafenib [4,5], pazopanib [2,6], bevacizumab [7,8], axitinib [5] and tivozanib [9,10] – have changed the therapeutic landscape in metastatic renal-cell carcinoma (mRCC). Five out of six agents have been approved for either first-line (sunitinib, pazopanib and bevacizumab + interferon-alpha) or second-line (sorafenib, axitinib) treatment of metastatic or advanced RCC. With these novel strategies, the median overall survival of patients has increased considerably, often, however, at the expense of chronic side-effects. Common treatment-related side-effects include: (1) general symptoms such as fatigue and asthenia, (2) gastrointestinal symptoms such as diarrhoea and stomatitis, (3) skin toxicities, (4) cardiovascular toxicities and (5) a variety of laboratory abnormalities. Some of these side-effects are clinically highly relevant because they may jeopardise the patient’s safety or quality of life, while others may have little clinical relevance. Treating physicians need to be aware of potential side-effects that may occur, how to prevent and/or manage them, and the clinical implications for the ongoing treatment. This is of paramount importance since dose reductions and treatment discontinuations may significantly affect the outcome [11].

2. Incidence of toxicities associated with VEGF inhibitors

Toxicities reported from VEGFR inhibitors in mRCC are outlined in Table 1. Among general symptoms, fatigue (and/or asthenia) has been most commonly reported for sunitinib (up to 63% all grades; grade ≥3: 17%), followed by axitinib (all grades 39%, grade ≥3: 11%) and sorafenib (all grades 37%; grade ≥3: 5%). A high incidence of fatigue has also been reported from the combination of bevacizumab + interferon-alpha (IFNα). However, the incidence of fatigue appears to be low in patients being treated with bevacizumab alone [12,13]; thus, this side-effect may be attributed to IFNα rather than bevacizumab. Interestingly, the newest VEGFR–tyrosine kinase inhibitor (TKI) tivozanib appears to have little effect on fatigue levels (all grades: up to 18%, grade ≥3: 5%).

Gastrointestinal side-effects are extremely common in patients on VEGFR–TKI treatment. In particular, sunitinib and axitinib were shown to cause reduced appetite and/or anorexia (up to 34% of the patients). In the case of sorafenib, this may be caused partly by the high incidence of stomatitis and/or dysgeusia (30% and 46%, respectively). Diarrhoea is another frequent gastrointestinal toxicity: high incidences of all grades of diarrhoea were reported from patients on sunitinib (61%), sorafenib (53%), pazopanib (63%) and axitinib 55%, again with quite a favourable profile for tivozanib (22%).

The most common skin toxicities caused by VEGFR inhibitors are hand–foot syndrome (HFS), skin- and/or hair-depigmentation and rash. The highest incidence of all grades of HFS has been reported from sorafenib (51%) and sunitinib patients (50%), with a higher grade 3 + 4 HFS incidence in sorafenib patients (16%). Similarly, sorafenib was shown to cause rash in up to 32% of patients (all grades). Hair and/or skin depigmentation is commonly observed in patients on pazopanib (up to 38%) and sunitinib (up to 27%).

Among the group of cardiovascular, lung and laryngeal side-effects, hypertension is the most common (up to 46%). Hypertension has been observed with all of these agents and has been considered a fairly reliable biomarker for response, progression-free survival (PFS) and overall survival (OS) [14]. The highest incidence of grades 3 + 4 hypertension has been observed with tivozanib (26%). Cardiac side-effects include congestive heart failure (sunitinib: 13%) and ischaemia or myocardial infarction (sorafenib: 3%; bevacizumab + interferon-alpha 1%). Bleeding events, most commonly epistaxis, have been observed in patients treated with bevacizumab + IFN, sunitinib and sorafenib (33%, 18% and 15%, respectively). While dyspnoea is a common side-effect of mTOR-inhibitors, the incidence is low in patients with VEGFR inhibitors. No direct effect of these agents on lung tissue has been reported so far; thus, the occurrence of dyspnoea might be a secondary event due to lung metastases or...
oedema as a result of high-grade hypertension or congestive heart failure. In contrast, dysphonia is a common side-effect of new-generation TKIs such as axitinib (31%) and tivozanib (22%).

The incidence of grade 3 + 4 myelotoxicity is low with VEGF-R inhibitors when compared to classical cancer treatment such as chemotherapy. Nevertheless, multikinase inhibitors, particularly sunitinib, may induce grade 3 + 4 anaemia (8%), neutropenia (18%), thrombocytopenia (9%) and lymphopaenia (18%). Infections, however, have not been reported yet.

Various metabolic and laboratory abnormalities have been shown to occur in patients treated with VEGFR inhibitors. These include renal and electrolyte abnormalities such as creatinine increase (up to 70%), proteinuria (71%), abnormalities

| Table 1 – Toxicities reported from phase III trials (%) | Sunitinib [1–3] | Sorafenib [4,5] | Pazopanib [2,6] | Bevacizumab + IFN- alpha [7,8] | Axitinib [9] | Tivozanib [9,10] |
|-------------------------------------------------------|----------------|----------------|----------------|-------------------------------|------------|-----------------|
| Grade(s) in % | Grade(s) in % | Grade(s) in % | Grade(s) in % | Grade(s) in % | Grade(s) in % | Grade(s) in % |
| Adverse events | All | 3 + 4 | All | 3 + 4 | All | 3 + 4 | All | 3 + 4 | All | 3 + 4 |
| General and others | | | | | | | | | | |
| Fatigue | 51/63/54 | 7/17/13 | 37/32 | 5/5 | 19/55 | 2/10 | 33/93 | 12/37 | 39 | 11 |
| Asthenia | 17/mr/20 | 4/mr/7 | nr/14 | nr/3 | 14/mr | 21 | 10/4 | 25 | 2 | 8/18 |
| Weight loss | nr/12 | nr/4/6 | nr/12 | nr/3 | nr/12 | nr/3 | nr/12 | nr/3 | nr/12 | nr/3 |
| Palpitations | 11/mr/14 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 |
| Depression | 7/mr/8 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Chills | 6/mr/7 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Myalgia | 5/mr/8 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Neurologic-sensory neuropathy | nr/mr | nr/mr | nr/mr | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Gastrointestinal [6] | | | | | | | | | | |
| Anorexia, decreased appetite | nr/31/34 | nr/3/2 | 16/29 | <1/4 | 22/37 | 2/1 | 36/71 | 3/17 | 34 | 5 |
| Dysgeusia or dry mouth | 11/36/46 | 0/0/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Stomatitis | 25/mr/30 | 1/mr/1 | nr/12 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Nausea | 44/56/2 | 3/2/5 | 3/2 | <1/1 | 26/45 | <1/2 | 10/57 | 24 | 3 |
| Vomiting | 24/mr/31 | 4/mr/4 | 16/17 | 1/1 | 21/12 | 4.2 | ne | nr/2 |
| Diarrhoea | 33/57/8 | 5/7/10 | 43/33 | 2/2 | 52/63 | 3.8 | 20/40 | 2/40 | 35 | 11 |
| Constipation | 15/mr/12 | 15/0 | 3/1 | 1/0 | 1/0 | 1/0 | 1/0 | 1/0 | 1/0 | 1/0 |
| GI perforation | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er |
| Skin | | | | | | | | | | |
| HS3 | 20/20/29 | 2/mr/4 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 |
| Rash | 20/20/29 | 2/mr/4 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 | 3/mr/5 |
| Alopecia | nr/12 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 |
| Depigmentation | 16/10/27 | 1/mr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 | nr/1 |
| Priapism | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er |
| Dry skin | 16/mr/11 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 |
| Wound healing complications | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er |
| Cardiovascular, lung, laryngeal | | | | | | | | | | |
| Hypertension | 24/42/90 | 8/15/22 | 17/29 | 4/11 | 40/46 | 4/15 and <1 | 26/28 | 3/11 | 40 | 16 |
| CHF | 10/mr/13 | 2/mr/4 | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er |
| Cardiac ischaemia | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er |
| Cerebrovascular ischaemia | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er |
| Embolism/thrombosis | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er | nr/er |
| V = venous A = arterial | | | | | | | | | | |
| Bleeding | 12/mr/18 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 | 1/mr/1 |
| Dyspnoea | nr/10 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 |
| Cough | nr/10 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 |
| Pneumonia | nr/10 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 |
| Dysphonia | nr/10 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 | nr/0 |
| Anaemia | 71/60/79 | 4/mr/8 | 6/51 | nr/1 | 3/4 | nr | nr | 10/16 | 3/4 | 15 |
| Haemoglobin elevation | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er | nr/er/er |

(Continued on next page)
in sodium, potassium, magnesium and calcium levels in up to
37%, 50%, 31% and 59%, respectively. In addition, pazopanib,
sunitinib and tivozanib in particular were shown to cause in-
creased levels of bilirubin, alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) in up to 36%, 60% and
61% of the patients, respectively. In the case of tivozanib,
international normalised ratio (INR) and partial thrombo-
plastin time (PTT) abnormalities were also reported (82%
and 53%, respectively). Sunitinib, sorafenib and tivozanib
were shown to increase amylase and lipase levels in approx-
imately 50% of patients. Finally, the induction of hypothyroid-
ism is an observation that may have been underreported in
the pivotal trials; in later analyses, up to 36% of patients
was shown to develop hypothyroidism[15]. As with hyperten-
sion, the occurrence of hypothyroidism has been linked to a
better outcome[15,17].

3. The severity of side-effects and their impact
on outcome

The occurrence of grade 3 + 4 toxicities, and to some extent
also toxicities of lower grades, may tempt clinicians to reduce
the dose, or to interrupt or discontinue treatment. Table 2 out-
lines the incidence of dose reductions and interruptions, the
rate and most common reasons for treatment discontinua-
tions, as well as the most common toxicities that have led
to death. Dose reductions occurred in up to 51% of sunitinib
patients, 52% of sorafenib patients, 44% of pazopanib pa-
tients, 31% of axitinib patients and 14% of tivozanib patients,
while no dose reductions of bevacizumab were permitted in
the Bevacizumab plus interferon alfa-2a for treatment of met-
astatic renal cell carcinoma: a randomised, double-blind
phase III trial (AVOREN) and CALGB bevacizumab trials. Sim-
ilarly, dose interruptions and treatment delays were required
in 38% of sunitinib patients, 80% sorafenib patients, 62% bev-
acizumab + IFN patients and 77% of axitinib patients. In con-
trast, the number of patients with dose interruptions was
considerably lower in tivozanib patients (18%). Both dose
reductions and treatment interruption may help to prevent
or manage treatment-associated side-effects. However, sev-
eral authors have shown that higher relative dose intensities
were associated with better outcome. A pharmacodynamic/
pharmacokinetic analysis including six sunitinib trials re-
vealed that response rates, time to progression and overall
survival increased with the mean daily exposure to sunitinib
[11]. Similarly, intra-patient dose-escalated sorafenib was
shown to exert promising antitumour activity and led to a
complete/partial response (CR–PR) rate of 48%, with eight
out of 44 patients achieving complete remission [18]. Finally,
Rini et al. could demonstrate in a randomised phase II study
that axitinib dose titration significantly improved overall re-
sponse rates when compared to placebo in patients eligible

### Table 1 (continued)

| Leukopenia | 78/78/78 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 |
|-----------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Neutropenia | 72/73/73 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 |
| Thrombocytopenia | 65/68/68 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 |
| Lymphopenia | 60/55/68 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 | 6/11/8 |

### Metabolic and laboratory abnormalities

| Bilirubin | 78/78/78 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 |
|-----------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ALT       | 43/45/51 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 |
| Gamma-GT  | 78/78/78 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 |
| INR       | 78/78/78 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 |
| PTT       | 78/78/78 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 | 7/11/8 |
| Increased alkaline phosphatase | 43/45/51 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 | 4/11/8 |

### 3. The severity of side-effects and their impact on outcome

The occurrence of grade 3 + 4 toxicities, and to some extent
also toxicities of lower grades, may tempt clinicians to reduce
the dose, or to interrupt or discontinue treatment. Table 2 out-
lines the incidence of dose reductions and interruptions, the
rate and most common reasons for treatment discontinua-
tions, as well as the most common toxicities that have led
|                        | Sunitinib [1–3] | Sorafenib [4,5] | Pazopanib [2,6] | Bevacizumab [7,8] | Axitinib [5] | Tivozanib [9,10] |
|------------------------|----------------|----------------|----------------|------------------|-------------|-----------------|
| **Dose reduction**     |                |                |                |                  |             |                 |
| due to AEs (%)         | 32 [1]         | 13 [4]         | 44 [2]         | Not permitted   | 31          | 8 [9]           |
|                        | 51 [2]         | 52 [5]         |                |                  |             | 13.9 [10]       |
|                        | 50 [3]         |                |                |                  |             |                 |
| **Dose interruptions** |                |                |                |                  |             |                 |
| (treatment delays)     | 38 [1]         | 21 [4]         | nr             | nr [7]           | 77          | 4 [9]           |
|                        |                | for dermatological |               | nr [7]           |             | 18 [10]         |
|                        |                | events, 80 for GI |               | 61.7 [8]         |             |                 |
|                        |                | events [5]     |                |                  |             |                 |
| **Discontinuation**    |                |                |                |                  |             |                 |
| due to AEs             | 8 [1]          | 10 [4]         | 12 [5]         | 28 [7] any       | 4           | 9 [9]           |
|                        | 19 [2]         | 8 [5]          | 24 [2]         | 19 [7] bevacizumab |             | 4 [10]         |
|                        |                |                |                | 23 [8]           |             |                 |
| Most common reason for|                |                |                |                  |             |                 |
| discontinuation        | Cytopaenia [2] | Constitutional | Liver events [2]|                  | Fatigue, and| nr [9,10]       |
|                        |                | [4], gastrointestine | [2]             |                  | transient   |                 |
|                        |                | al [4], dermatologic | [2]             |                  | ischaemic attack |
|                        |                | [4], respiratory | [2]             |                  |                 |
|                        |                | tract symptoms  | [2]             |                  |                 |
|                        |                | HFS [5], diarrhoea | [2]             |                  |                 |
|                        |                | [5], asthenia [5]| [2]             |                  |                 |
|                        |                | 34 [4]         |                |                  |                 |
| AEs leading to         |                |                |                |                  |             |                 |
| hospitalisation or     | Renal failure  | 2 death from    | 4 [6]          | 2 [7] bleeding    | 0           |                 |
| non-PD related deaths  | [1] n = 1      | cardiac         | hepatic failure,| events n = 2, GI |             |                 |
|                        | Gastric        | ischaemia/      | hepatic failure,| perforation n = 1,|             |                 |
|                        | haemorrhage [1]| infarction [4]  | rectal          | myocardial       |             |                 |
|                        | n = 1          | 2 death [5]     | haemorrhage,    | infarction n = 1,|             |                 |
|                        | Respiratory    | from tumour      | peritonitis and | atrial fibrillation|             |                 |
|                        | failure [1]    | necrosis causing | bowel perforation| n = 1           |             |                 |
|                        | n = 1          | retroperitoneal  | bleeding and  n = 1 | pneumonia n = 1 |             |                 |
|                        | Sudden death   | bleeding        | GI bleeding    | hepatic failure  |             |                 |
|                        | [1] n = 1      |                 |                | (history of active hepatitis B) |     |                 |
|                        |                 |                 |                | n = 3 [8]        |             |                 |
| TX-related death       | Renal failure  | 2 death from    | 2 [7] bleeding | n [9]–8/272      |             |                 |
| or non-PD related       | [1] n = 1      | cardiac         | events n = 2, GI | ischaemic stroke  |             |                 |
| deaths                 | Gastric        | ischaemia/      | GI perforation n = 1, | n = 2, acute    |             |                 |
|                        | haemorrhage [1]| infarction [4]  | myocardial      | coronary         |             |                 |
|                        | n = 1          | 2 death [5]     | infarction n = 1,| syndrome, acute   |             |                 |
|                        | Respiratory    | from tumour     | atrial fibrillation| respiratory       |             |                 |
|                        | failure [1]    | necrosis causing| n = 1           | failure, cerebral |             |                 |
|                        | n = 1          | retroperitoneal | pneumonia n = 1 | vascular accident,|             |                 |
|                        |                 | bleeding        | hepatic failure | hypotension and   |             |                 |
|                        |                 |                 | (history of active hepatitis B) | pulmonary     |             |                 |
|                        |                 |                 |                 | embolism all n = 1 |             |                 |
|                        |                 |                 |                 | nr [10]          |             |                 |

nr, not reported.
for dose titration [19]. The challenge in the management of mRCC patients is to have a balanced approach to maintaining both dose intensity and safety of the patient.

4. Reasons for and incidence of dose adjustments and treatment discontinuation by agent

4.1. Sunitinib

In the final analysis of sunitinib versus IFN-alpha [3], 51% and 19% of sunitinib patients were reported to have required dose reductions or treatment discontinuation, respectively, because of adverse events. Causes of death apart from disease progression included acute renal failure \( n = 1 \), gastric haemorrhage \( n = 1 \), respiratory failure \( n = 1 \) and sudden death \( n = 1 \). In the COMPARZ trial, the most common reason for sunitinib discontinuation was cytopenia (3%).

4.2. Pazopanib

In the pivotal pazopanib trial [6] 33% and 4% of patients experienced grade 3 and 4 toxicities, respectively. The adverse event (AE) profile was similar in treatment-naive and cytokine-pretreated patients, although discontinuation rates because of AEs were higher in the cytokine-pretreated (19%) compared with the treatment-naive patients (12%). Arterial thromboembolic events occurred in 3% of pazopanib patients – myocardial infarction or ischaemia 2%, cerebrovascular accident <1% and transient ischaemic attack (TIA) <1% – compared with none in the placebo arm. The incidence of all-grade haemorrhagic events was 13% in the pazopanib arm versus 5% in the placebo arm. Deaths from adverse events were reported in 4% of pazopanib patients and in 3% in the placebo arm. Four pazopanib patients (1%) had fatal adverse events, including ischaemic stroke, abnormal hepatic function, rectal haemorrhage and peritonitis/bowel perforation. In the COMPARZ trial [2] dose reductions and treatment discontinuations occurred in 44% and 24% of patients, respectively. The most common reasons for pazopanib discontinuation were liver events (6%).

4.3. Sorafenib

In the TARGET trial [4] 10% of sorafenib patients had to discontinue the treatment, mostly because of constitutional, gastrointestinal, dermatological or pulmonary upper respiratory tract symptoms. Dose reductions occurred in 13% of sorafenib patients versus 3% of placebo patients \( P < 0.001 \), and dose interruptions because of adverse events occurred in 21% of sorafenib patients versus 6% of placebo patients \( P < 0.001 \). Dose interruptions were mostly because of HFS, rash or diarrhoea. Cardiac ischaemia occurred in 12 sorafenib patients (3%) and two patients in the placebo groups (<1%, \( P = 0.01 \)). Bleeding was more frequent in sorafenib than in placebo patients (15% versus 8%, respectively). In the axitinib phase III trial [5], the most frequent grade-3 and -4 adverse events associated with sorafenib were HFS, hypophosphataemia, lipase elevation and hypertension. Two treatment-related deaths occurred in sorafenib patients and were caused by necrosis with retroperitoneal bleeding and gastrointestinal haemorrhage.

4.4. Bevacizumab + IFN

In the AVOREN trial [7], serious adverse events occurred in 29% of patients who received bevacizumab versus 16% of those who did not. Similarly, AEs requiring treatment discontinuation were more frequent in bevacizumab-treated patients versus placebo patients (28% versus 12%). Grade 3 and 4 AEs in patients who received bevacizumab included four gastrointestinal perforations (1%; grade 4: \( n = 3 \)) and 10 thromboembolic events (3%; grade 4, \( n = 4 \)). Moreover, seven (2%) and 5% of bevacizumab patients discontinued treatment because of hypertension and proteinuria, respectively. Deaths due to AEs were reported in 2% of patients who received bevacizumab and 2% who did not. Three deaths (<1%) among the patients who received bevacizumab (\( n = 2 \) bleeding events and \( n = 1 \) gastrointestinal perforation) were thought to be associated with treatment. The other causes of death of bevacizumab-treated patients included myocardial infarction, atrial fibrillation, pneumonia, hepatic failure (in a patient with a history of hepatitis B) and staphylococcal sepsis.

In the CALGB trial [8] 80% of patients receiving bevacizumab experienced grade \( \geq 3 \) toxicities compared with 63% IFN patients \( P < 0.001 \). Bevacizumab resulted in significantly more grade \( \geq 3 \) hypertension (11% versus 0), anorexia (17% versus 8%), fatigue (37% versus 30%) and proteinuria (15% versus <1%). There were four treatment-related deaths in the IFN arm and three in the bevacizumab arm.

4.5. Axitinib

In the axitinib phase III trial [5], the most common AEs of grade \( \geq 3 \) were hypertension, diarrhoea and fatigue; 32% of axitinib patients had elevations in thyroid-stimulating hormone (TSH) and 27% required initiation or dose adjustments of thyroid hormone replacement. No treatment-related deaths occurred in the axitinib arm.

4.6. Tivozanib

In the phase II randomised discontinuation trial on tivozanib, the most common treatment-related toxicities were hypertension and dysphonia which occurred in 45% and 22% of patients, respectively. Grade 3 and 4 toxicities were rare and included hypertension (grade 3: 11%, grade 4: 1%) and laboratory abnormalities (5%). Dose reductions and interruptions were deemed necessary in 8% and 4% of patients, respectively. Treatment discontinuation because of adverse events occurred in 9% of patients. Causes of death that were not attributed to disease progression included ischaemic stroke (\( n = 2 \)), coronary syndrome, respiratory failure, cerebral vascular accident, hypotension and embolism (\( n = 1 \) each); however, none of these were associated with tivozanib treatment.

Understanding the pathophysiology of individual toxicities, and developing proactive strategies for their prevention and treatment are important aspects of disease management and may avoid dose reductions and treatment discontinuation.
Fatigue and to a slight extent asthenia are frequent symptoms. Targeted agents differ regarding their side-effect profile, and these differences may be attributed to the mode of action; the incidence and severity of side-effects may depend on the number of inhibited targets (single versus multikinase inhibitors), the type of inhibited target (VEGF inhibition versus platelet-derived growth factor, PDGF, inhibition versus Flt-3 inhibition, etc.) and the strength of target inhibition (affinity to the tyrosine kinase, ‘on- and off-target’ toxicities). While some toxicities have been linked to the inhibition of a specific target, e.g. hypertension and VEGF, the association of other side-effects with a particular target is less clear (e.g. stomatitis, diarrhoea). Moreover, the incidence and severity of side-effects may differ between patient populations depending on single-nucleotide polymorphisms.

5. Pathophysiology of selected side-effects (involved targets) and management

Targeted agents differ regarding their side-effect profile, and these differences may be attributed to the mode of action; the incidence and severity of side-effects may depend on the number of inhibited targets (single versus multikinase inhibitors), the type of inhibited target (VEGF inhibition versus platelet-derived growth factor, PDGF, inhibition versus Flt-3 inhibition, etc.) and the strength of target inhibition (affinity to the tyrosine kinase, ‘on- and off-target’ toxicities). While some toxicities have been linked to the inhibition of a specific target, e.g. hypertension and VEGF, the association of other side-effects with a particular target is less clear (e.g. stomatitis, diarrhoea). Moreover, the incidence and severity of side-effects may differ between patient populations depending on single-nucleotide polymorphisms.

5.1. Fatigue, asthenia

5.1.1. Mechanisms

Fatigue and to a slight extent asthenia are frequent symptoms in patients undergoing treatment with VEGF inhibitors. In 1998, Celli and colleagues described fatigue as a ‘subjective state of overwhelming and sustained exhaustion and decreased capacity for physical and mental work that is not relieved by rest’ [20]. Fatigue induced by VEGF inhibitors may indeed include more symptoms than tiring easily. Patient’s description of what their fatigue involves includes a loss of social interest, reduced voluntariness for physical activity, cognitive disorders, reduced appetite and depressive symptoms. Together, these symptoms have been described as sickness behaviour, a common status in patients with acute or chronic diseases [21]. In patients treated with VEGF inhibitors, many factors appear to contribute to fatigue and sickness behaviour. These include several biological processes related to the patient and/or the disease in which inflammation appears to have a major role. Moreover, treatment-related side-effects may contribute to fatigue and asthenia.

The underlying mechanisms appear to involve many aspects: (1) the individual genome of the patient, (2) disease-related factors, either biological or as a result of behavioural and psychological factors that may arise during the disease, (3) cancer treatment itself, which may induce fatigue either on the basis of the specific mode of action or secondarily by leading to side-effects that may be associated with the symptom of fatigue.

Several studies have investigated the relationship between genomic markers and fatigue. An association was found between functional interleukin-6 (IL-6) polymorphism and fatigue in patients and their relatives [22], while Aouizerat and colleagues found evidence for a genetic association between tumour necrosis factor alpha (TNF-a) and the severity of sleep disturbances and morning fatigue [23]. Furthermore, single-nucleotide polymorphisms (SNPs) of several cytokines – including Interleukin-1β, IL-1RN and IL-10 – showed associations with fatigue levels in lung cancer patients [24]. So far, no genomic markers for fatigue have been identified in patients undergoing VEGF inhibitor treatment.

Fatigue has also been strongly correlated with depression in cancer patients [25], and increased stress-induced inflammatory responses were observed in patients with major depression and stress [26]. Moreover, acute psychological stress was shown to influence pro-inflammatory cytokines [27]. Finally, physical inactivity and increased body mass index have been associated with fatigue in patients with breast cancer [28]. Again, no data have been obtained so far with respect to patients treated with VEGF inhibitors.

Many tumour types have been shown to promote progression though inflammatory cells [29]. Chemokines and cytokines were shown to attract immune cells to tumour cells [30], thereby leading to immune-cell dysfunction [31]. Research on neuro-immune signalling has linked pro-inflammatory cytokines with the development of fatigue. For instance, sickness has been shown to be triggered by IL-1α and β, TNFα and IL-6 [32–34]. Although no studies have been undertaken in patients undergoing anti-VEGF treatment, IL-6 levels have been linked to disease progression in patients with mRCC [25].

Cancer treatment itself is known to induce fatigue. Induction of chronic inflammation has also been recognised as a treatment-related factor that may induce fatigue through pro-inflammatory cytokines produced by monocytes [36]. Wang et al. measured markers of inflammation in patients with gastrointestinal cancers undergoing chemotherapy and their relationship with fatigue. They found that serum concentrations of TNF-R1 were associated with the severity of fatigue [37]. Similar findings have been reported by various other authors with regards to C-reactive protein (CRP) levels, IL-6, etc. It is currently unknown as to whether VEGFR inhibitors can trigger fatigue through inflammation.

Various side-effects associated with VEGF inhibitors may contribute to fatigue and sickness behaviour; persistent fatigue is a common symptom of patients with hypothyroidism [38] and several VEGF inhibitors have been shown to induce hypothyroidism (Table 1). Similarly, hypophosphataemia is frequently observed in patients treated with VEGF inhibitors. Although a low serum phosphate level does not necessarily correlate with clinically relevant total body phosphate depletion, it should be considered that hypophosphataemia may cause muscle weakness [39]. Muscular dysfunction has also been shown to involve the heart [40] by causing myocardial changes and a reversible reduced sensitivity to catecholamines [40]. Muscle weakness may also be explained by an impaired muscle glucose uptake. Muscle activity involves an increased rate of glucose uptake in the contracting muscle. This is enabled by glucose transporter recruitment [41]. Multikinase inhibitors may interfere with signals required for this process, such as protein kinase C, nitric oxide, etc. [42]. Furthermore, TKI-induced hypoglycaemia may also contribute to muscular weakness. Sunitinib, for instance, was shown to decrease blood glucose levels [43]. In a clinical study that sought to distinguish between a central and peripheral cause of fatigue, Yavuszen et al. [44] found that patients with cancer-related fatigue had a greater central fatigue, indicated by shorter endurance time. Central fatigue has been linked to a loss of voluntarily activated muscles because of mechanisms proximal to the neuromuscular junction. On the other hand, muscle fatigue may have a peripheral cause, e.g. due to...
metabolic changes within the muscles. Antoun et al. [45] could demonstrate that treatment with sorafenib exacerbates excessive muscle loss and that this loss increased during the course of treatment. A possible explanation for this phenomenon is that VEGF inhibition leads to downstream inhibition of AKT and mTOR, which are of paramount importance for skeletal muscle hypertrophy and muscle protein synthesis [46].

Finally, malnutrition as a result of VEGF-inhibitor-induced anorexia, anaemia and dehydration caused by diarrhoea may account for the high incidence of fatigue, asthenia and sickness behaviour in patients undergoing VEGF inhibitor treatment.

5.1.2. Management
Effective treatment for fatigue includes pharmaceutical and non-pharmaceutical interventions.

5.1.2.1. Non-pharmacological interventions. Patterson and colleagues [47] recently reviewed studies that looked at the impact of eight different types of intervention on fatigue levels. These interventions included (1) psycho-education, (2) cognitive behavioural therapy, (3) exercise combined with education and support, (4) exercise alone, (5) acupressure, (6) energy conservation and activity management, (7) relaxation breathing exercises and (8) distraction. With the exception of cognitive behavioural therapy, all of the above-mentioned non-pharmacological interventions were found to effectively reduce fatigue in patients with various diseases. In particular the impact of exercise has been well studied in cancer patients revealed an impact of these interventions and positive effects on muscular function and body composition. These effects were accompanied by a decrease in CRP levels and an improvement in energy levels [55]. Attempts to interfere with muscle wasting have been made with l-carnitine supplementation, which was shown to have beneficial effects by improving nitrogen balance via increased protein synthesis or reduced protein degradation, inhibition of myonuclear apoptosis and interference with inflammation. Finally, any intervention that reduces the incidence and severity of fatigue-inducing side-effects may secondarily help to reduce fatigue levels: this includes control of anaemia, diarrhoea, hypothyroidism, hypophosphataemia, congestive heart failure and malnutrition.

5.1.2.2. Pharmacological interventions. The finding that fatigue is the administration of thyrotropin-releasing hormone (TRH). TRH was shown to be involved in the biological processes of cytokine-induced sickness behaviour [55], and the administration of TRH has been associated with a significant improvement in fatigue levels, sleep disturbances and quality of life. These effects were accompanied by a decrease in CRP levels and an increase in after-load. An
involvement of an up-regulated renin–angiotensin–axis resulting from glomerular ischaemia has also been discussed as a potential mechanism for the development of hypertension. However, Kappers and colleagues demonstrated that a sunitinib-induced increase in blood pressure is accompanied by a decrease in renin [65]. The same group also showed that sunitinib was associated with a considerable rise in endothelin-1 levels. In a rat model, pretreatment with atrasentan, an endothelin-A receptor antagonist, completely prevented a TKI-induced rise in blood pressure [66].

5.2.2. Management

Patients undergoing VEGF inhibitor treatment should be checked for existing blood pressure and informed about the importance of monitoring and treating blood pressure. Home monitoring has been recommended as a reasonable method to closely monitor blood pressure. Recommendations regarding the frequency of measurements vary between three times daily [67] to once weekly [68]. Accepted thresholds for initiating antihypertensive treatment are blood pressures of ≥140/90 mmHg and 130/80 in patients with diabetes or chronic renal failure [67,69]. The selection of a specific antihypertensive drug should be based on the general cardiovascular status of the patient, as assessed by electrocardiogram (ECG) and echocardiography before treatment [67]. According to the practice guidelines for the management of arterial hypertension [70], the choice of antihypertensive treatment should be based on the underlying cardiovascular co-morbidity. Other recommendations for optimal treatment may be based on considerations of the underlying pathological mechanisms. As VEGF inhibitors also induce proteinuria, angiotensin-converting enzyme (ACE) inhibitors may be considered appropriate: ACE inhibitors were shown to improve nephrin expression and to improve endothelial function [71]. Angiotensin inhibitors as well as angiotensin-receptor blockers may have an additional advantage since they were shown to exert antitumour activity (also discussed in section on proteinuria). Calcium-channel blockers such as nifedipine may offer the (vascular) advantage of VEGF secretion from coronary smooth muscles cells [72]. In contrast, non-dihydropyridine calcium-channel blockers such as verapamil or diltiazem should be avoided: being Cytochrome P540 3A4 (CYP3A4) inhibitors, they may interfere with the tumour drug metabolism. Finally, it is important to inform the patient to withhold antihypertensive medication in off-treatment periods, where blood pressure mostly normalises.

5.3. Proteinuria

5.3.1. Mechanism

Although proteinuria has been understood as a classical on-target side-effect, such as hypertension, little has been reported from the pivotal RCC studies. This could be due either to the lack of systematic assessment of proteinuria during the trials or to a low incidence, leading to a drop-out from the toxicity tables. No data on proteinuria have been published in the randomised trials of sunitinib, sorafenib, bevacizumab + IFNα and axitinib; in contrast, proteinuria has been noted as a common side-effect in the pazopanib and tivozanib trials trials, with an all-grade incidence up to 71% and a grade 3 + 4 incidence up to 15%. As proteinuria has been linked to VEGF inhibition, it is likely that all of these agents induce proteinuria to a considerable extent. Several mechanisms have been summarised in a comprehensive review on proteinuria induced by VEGF signalling inhibition by Izedine et al. [73], and include (1) inhibition of VEGF on podocytes which results in loss of endothelial fenestrations in glomerular capillaries, endotheliosis, loss of podocytes and proteinuria [74,75], (2) an anti-VEGF treatment-induced glomerular endothelial cell detachment and hypertrophy [76], (3) a subacute glomerular thrombotic microangiopathy [73] and (4) an adaptive hyperfiltration response to nephrectomy [73].

5.3.2. Management

Any abnormal proteinuria may not only trigger loss of kidney function, it also represents a considerable risk for renal disease and cardiovascular morbidities. In patients with chronic renal disease, structural and functional cardiac changes have been linked to persistent pressure and volume overload [77]. Moreover, strong association between proteinuria and subsequent risk of coronary artery disease have been confirmed in a meta-analysis involving 169,949 patients; in this analysis, the presence of proteinuria was associated with a 50% increased risk for coronary artery events [78]. VEGF inhibitors have enabled many patients to live long enough to experience such additional drug-induced diseases. Thus, both regular monitoring for proteinuria as well as thorough management of proteinuria appears mandatory in patients under chronic VEGF inhibitor treatment. It has been recommended that patients should be assessed for existing kidney disease prior to the start of the treatment [73], and that a dipstick analysis and/or quantitative protein test analysis be performed before each cycle of VEGF inhibitor treatment. In the case of isolated proteinuria of <1 g/L, anti-VEGF treatment might be continued along with continued monitoring. In the case of proteinuria ≥1 g/L or proteinuria with microscopic haematuria, a nephrologist should be involved who may decide on whether to perform biopsy. Treatment recommendations include ACE inhibitors or angiotensin-2 receptor antagonists which were both shown to reduce proteinuria [79,80]. Additional measures may include salt restriction and the use of dexamethasone, which may stabilise the podocyte cytoskeleton [81].

5.4. Cardiac toxicities

5.4.1. Mechanism

Cardiac toxicities occurring under VEGFR inhibitors may be the result of both on-target and off-target inhibition. Several kinases inhibited by multikinase inhibitors such as VEGF, Hypoxia-inducible factor (HIF), PDGF and KIT are physiologically highly relevant for the heart, and the inhibition of these kinases may impair compensatory mechanisms [82–84]. HIF inhibition, for instance, may cause cardiac toxicity since in the cardiovascular system HIF-related gene products are understood as mediators of myocardial response to acute or chronic ischaemia, myocardial remodelling, peri-infarct vascularisation and vascular permeability. Thus, inhibition of these kinases may impair the myocardial response to acute or chronic ischaemia [82–85]. Disruption of PDGF–platelet derived growth factor receptor (PDGFR) signalling may lead to
apoptosis and necrosis of the cardiac myocyte. PDGFR is expressed on cardiac myocytes and endothelial cells. Sunitinib-induced inhibition of S6 kinase may lead to the release of pro-apoptotic factor Apoptosis-regulator (BCL2) antagonist of cell death, BCL2-associated X protein activation and cytochrome C release and activation of the intrinsic apoptotic pathway and cell death [86]. Disruption of KIT signalling may cause cardiac damage by inhibiting repair mechanisms. KIT is expressed on endothelial progenitor cells, and functioning of the KIT receptor might be necessary for the mobilisation of endothelial progenitor cells to sites of injury. Inhibition of KIT was shown to aggravate myocardial remodelling and prevent repair [87–89]. Disruption of VEGF–VEGFR signalling in the heart may induce cardiac dysfunction by preventing compensatory hypertrophy; VEGF is relevant to capillary density in the myocardium and critical for stem-cell differentiation into cardiomyocytes [90,91]. In the murine model, disruption of VEGF–VEGFR signalling during imposition of the pressure load was shown to reduce capillary density, which in turn was associated with contractile dysfunction, fibrosis and heart failure. Thus, inhibition of VEGF–VEGFR signalling in the heart may become relevant to patients with poorly controlled hypertension. Finally, TKI-induced changes to the thyroid function may cause cardiac toxicity. Triiodothyronine has a direct effect on the cardiomyocytes. Any T3 depletion could cause changes at the nuclear level of the myocyte level by influencing T3-regulated transcription of genes that encode Ca^2+-ATPase exchanger, Na^+/-K^+--ATPase and voltage-gated potassium channels. Moreover, T3 exerts important non-nuclear functions on the myocyte which include ion channels for sodium, potassium and calcium [92]. Finally, low serum T3 levels have been shown to be the single and the most significant predictor of cardiovascular and all-cause mortalities in adults with heart disease [93]. Triiodothyronine also directly affects vascular smooth muscle cells, promoting relaxation [94]. Hypothyroidism was shown to increase vascular resistance [94,95] and to exert endothelial dysfunction due to reduced nitric oxide availability [96,97].

5.4.2. Management

The management of cardiac toxicities may vary among patients and may depend on the drug that has been used, potential existing co-morbidities and concomitant medications that may trigger cardiac events. The clinical presentation may vary as well: a decrease in left ventricular ejection fraction was noticed in 13% of the patients in the sunitinib phase III study [3]. In the target trial on sorafenib versus placebo, 3% of patients experienced cardiac ischaemia or myocardial infarction. Other investigators noticed arrhythmias and conduction disturbances, ST-segment or T-wave changes [84]. Based on the variety of clinical manifestations of cardiac toxicities, no general recommendation can be made. However, this side-effect clearly requires a multidisciplinary approach between oncologist and cardiologist. The risk of developing a cardiac event during TKI treatment should be assessed prior to treatment. On the other hand, patients with existing cardiac co-morbidities should not be deprived of effective cancer treatment. Early management of hypertension and proteinuria appears mandatory to reduce the risk of a cardiac event during TKI treatment. Congestive heart failure that develops under TKI treatment is generally completely reversible but requires treatment interruption and effective management [98]. TKI treatment can usually be resumed after recovery, but should be initiated carefully with close monitoring of the patient. Cardiac ischaemia and myocardial infarction also require treatment interruption and cardiological care. Upon recovery of the patient, the oncologist and cardiologist need to discuss the conditions under which the patient might be able to resume RCC treatment. The concomitant use of aspirin and/or clopidogrel should not necessarily represent a contraindication; however, increased risks for haemorrhage need to be carefully considered. In patients who have experienced either congestive heart failure or myocardial ischaemia or infarction, regular echocardiograms and electrocardiograms should be obtained; the value of cardiac troponin T, Creatine kinase (CK)-MB pro-B-type Natriuretic Peptide (BNP) is questionable. Many patients on TKI smay have increased serum levels of one or all of these markers; however, for various reasons, not all of them are clinically relevant. In asymptomatic patients with increased cTNT, CK-MB and pro-BNP treatment discontinuation should be avoided. Cardiac events under TKI treatment may not require a different approach to that offered to a patient without cancer. The only difference is that: (1) oncological treatment should be temporarily interrupted, and (2) treatment should be resumed upon recovery along with permanent cardiac co-medication and close cardiac monitoring of the patient. In this context, oncologists need to be aware that some agents, particularly anti-arrhythmic agents, may exert additive toxicities: e.g. some patients may receive amiodarone after a cardiac event. Amiodarone and sotalol are agents that prolong QT intervals, thus increasing the risk for torsades de pointes. Sunitinib is also an agent with a possible risk of torsades de pointes. Given together, the risk for torsades might be higher than with each drug alone. Changes in toxicity or activity profile may also result from concomitant cardiac medication. Calcium channel blockers such as diltiazem or verapamil and again amiodarone may be CYP3A4 inhibitors; concomitant use of these agents with sunitinib may require reduction in the dose of sunitinib. In most cases, patients can be effectively treated for both the cardiac event and the oncological condition. It is of paramount importance to inform the cardiologist about the necessity of these agents for the patient and about the change these agents have made to the prognosis of mRCC patients. Discontinuing RCC treatment should be regarded as the worst-case scenario.

5.5. Diarrhoea

5.5.1. Mechanism

In contrast to pure VEGF inhibitors such as bevacizumab, diarrhoea is a frequent side-effect of multikinase inhibitors. The underlying mechanism has not been elucidated so far and may require systematic bowel biopsies and stool analyses from patients treated with VEGF inhibitors. As both highly selective VEGFR-TKIs as well as less selective TKIs were shown to induce diarrhoea; it is also unclear as to whether this toxicity should be attributed to VEGF inhibition or off-target inhibition (e.g. PDGFR, KIT, etc.). VEGF and VEGF receptors were shown to be highly expressed in adult organs,
The management of TKI-induced diarrhoea includes dietary measures, probiotics and drugs. Although dietary measures are the avoidance of food and drinks that may cause bowel movements, such as raw fruits, lactose-containing foods, spicy foods, foods high in fibre and an increase in bananas, rice, potatoes, etc. [107]. Another dietary measure is the increased consumption of grated oxidised apples. A randomised double-blinded trial conducted in children revealed that the oxidised apples significantly reduced stool frequency in the treatment group compared to the control group [108]. Probiotics have been shown to prevent diarrhoea in inflammatory bowel disease [109]. Preclinical data yielded a similar efficacy in chemotherapy-induced diarrhoea [110,111]. In the clinical setting, Lactobacillus rhamnosus and fibre were shown to significantly reduce the incidence of grade 3/4 diarrhoea (37% versus 22%) in a randomised study in patients with colorectal cancer and chemotherapy [109]. While the use of probiotics has never been investigated in TKI patients, individual patients report considerable benefits.

Although several medical strategies have been established to manage diarrhoea in general, none of these have been investigated with regard to TKI-induced diarrhoea. One of the most commonly used agents is loperamide, which slows transit by decreasing the tone of the longitudinal muscles and increasing the tone of circular smooth muscles of the intestinal wall [112]. This increases the time substances remain in the intestines, allowing for more water to be absorbed. Loperamide also decreases colonic movements and suppresses the gastrocolic reflux. In mRCC treatment, patient’s satisfaction with this therapeutic measure has never been investigated and appears to vary. In clinical practice, some patients report that loperamide successfully controls higher grades of diarrhoea, while others complain that in the case of watery stools a slower transit is perceived as a larger burden than an increased stool frequency. Other medical strategies to manage or prevent diarrhoea include the use of budesonide, a topical corticosteroid which was shown to reduce bowel inflammation in patients with chemotherapy-induced diarrhoea. Budesonide was shown to reduce the grade of diarrhoea in >50% in loperamide-refractory patients treated with chemotherapy [113,114]. There are no data of budesonide in patients on TKI-induced diarrhoea. Another agent with unknown benefit in TKI patients is octreotide, a synthetic somatostatin that is approved for the treatment of diarrhoea related to vasoactive intestinal peptide (VIP)-secreting tumours and symptoms due to carcinoid syndrome. Octreotide was shown to decrease the secretion of VIP to prolong intestinal transit time and to reduce secretion and increase the absorption of fluid and electrolytes [115]. In patients with colorectal cancer receiving 5-Fluorouracil (FU)-based chemoradiation, no difference from placebo was found [116]. Finally, in patients who complain of bowel movements during meals or right after, a pancreatic insufficiency induced by the VEGFR inhibitor might be considered. In this case, treatment with pancreatic might be helpful (5 meals per day, 25,000 U pancreatin with each meal).

5.6. Anorexia

5.6.1. Mechanisms
As with fatigue, anorexia is regarded as a common and multifactorial phenomenon in tumour patients. Anorexia is part of a syndrome often referred to as anorexia–cachexia and involves metabolic and behavioural factors [117]. Anorexia–cachexia has been strongly linked to an interplay between cytokines, tumour products that induce lipolysis and/or protein degradation and neuropeptides [117–119]. TNFα was shown to induce lipid depletion in white adipose tissue [120]. Moreover, TNFα induces IL-6 secretion, which was found to be significantly elevated in patients reporting weight loss [121]. In a murine model, the cytokine IL-1 was shown to induce body weight loss [122]. These cytokines appear to induce anorexia by both their peripheral as well as their central effects [123]. In addition, several neuropeptide dysregulations have been associated with anorexia. Body weight was shown to be regulated by interactions between various orexigenic and anorexigenic central and peripheral neuropeptides [119]. Whether these interactions are influenced by VEGF inhibitors has not yet been elucidated.

5.6.2. Management
Several strategies have been investigated regarding their impact on anorexia–cachexia. These include medroxyprogesterone acetate, eicosapentanoic acid, l-carnitine and thalidomide. A randomised trial that aimed to identify the most effective among these strategies revealed the greatest benefits with a combination of all [124]. Medroxyprogesterone acetate (MPA) for instance was shown to increase body weight and appetite in patients with the cachexia–anorexia syndrome [125]. The underlying mechanism may involve a...
down-regulation of high serum levels of IL-6 and TNF-α [124]. As MPA has been shown to be increased upon the occurrence of resistance to TKI treatment in mRCC patients [124], the use of this agent may potentially act synergistically with TKIs by preventing or delaying resistance.

5.7. Stomatitis

5.7.1. Mechanisms and presentation
Patients on targeted agents may frequently report changes in the oral mucosa. The symptoms typically differ from chemotherapy-induced stomatitis. It also appears that changes differ between VEGF-TKIs and mTOR inhibitors. In sunitinib patients ulcers, taste alterations and cheilitis have been described [126]. In contrast, oral changes induced by mTOR inhibitors appear differently as superficial ulcers similar to aphthous stomatitis [127].

Dysgeusia or aguesia is quite common in patients undergoing sunitinib treatment. This is a taste disorder where e.g. the taste of meat may be perceived as sweet or a salty taste is not sensed at all. Other VEGFR-TKI patients may complain of oral burning with or without visible signs of inflammation [2, 128, 129]. Although stomatitis is completely reversible and more or less harmless, it is considered as clinically highly relevant since it often impairs the patient's quality of life. Moreover, permanent stomatitis or dysgeusia may contribute to chronic refusal of food intake, thereby leading to malnutrition, fatigue and anorexia. As stomatitis resolves rapidly once the drug is withheld or dose-reduced [126], physicians and patients might be tempted to accept treatment delays, dose modifications or even a change of treatment. However, such strategies may affect the outcome. Little is known of the mechanism of stomatitis induced by VEGF inhibitors. Apart from a reduction in the capillary network of the tongue, other mechanisms may contribute to this AE. Interestingly, oral changes – e.g. burning mouth syndrome (BMS) – have also been linked to hypothyroidism [130]. BMS has been characterised by oral burning with or without inflammation, frequently affecting women. In their study, Femiano and colleagues revealed that 85 patients with BMS had thyroid alterations when compared to 13 patients in the control group. Apparently, patients with BMS are affected by dysgeusia, a phenomenon that occurs frequently with tyrosine-kinase inhibitors [131]. Thyroid hormones have been shown to influence the maturation and specialisation of the taste buds [132], and it has been speculated that hypothyroidism could therefore lead to a reduction in taste. Other investigators [133] have suggested a dysfunction of the nigrostriatal dopaminergic pathway that may account for the development of BMS. In a study on patients with BMS, Lauria and colleagues detected a lower density of epithelial nerve fibres and axonal degeneration on biopsy of the tongue and suggested that BMS is caused by a trigeminal small-fibre sensory neuropathy. In a randomised placebo-controlled study, the topical administration of clonazepam improved symptoms in two thirds of BMS patients [135]. Finally, based on the assumption that BMS is caused by a dysfunction of the dopaminergic central nervous system, anti-epileptic drugs have been investigated [136]. Lopez and colleagues reported on a considerable improvement in BMS after treatment with pregabalin. Other mechanisms that have been discussed include shifts in the oral mucosa due to myelosupression [137], shifts in the ecological balance of oral and gut flora [138], an up-regulation of pro-inflammatory cytokines following cancer treatment [139] followed by NF-κB and cyclooxygenase-2 up-regulation. It remains unclear whether and in what way VEGFR inhibitors are involved in various processes that have been linked to stomatitis.

5.7.2. Management
Recommendations on how to treat or prevent stomatitis most commonly stem from experiences made in patients undergoing chemotherapy. General recommendations include, among others, the avoidance of spicy food, etc., the use of soft toothbrushes and appropriate dental hygiene [140]. No general recommendation exists for the prevention or management of dysgeusia. A review on drug-related taste disturbances in the elderly [141] revealed that zinc replacement might be helpful to enhance taste sensation for sweet, bitter and salty flavours. Patients with dysgeusia may benefit from niacin and vitamin A, and the use of mints, sugarless chewing gums and bicarbonate mouthwashes has been recommended as a palliative measure.

A meta-analysis on prophylactic agents to prevent stomatitis [142] identified 10 interventions that have positive effects on preventing or reducing mucositis. These included amifostine, Chinese herbal mixtures, hydrolytic enzymes such as trypsin, chymotrypsin, wobe-mugo and pepsin. Moreover, a recommendation has been made for ice chips. In patients with haematological malignancies undergoing high-dose chemotherapy, the use of keratinocyte growth factor-1 (palifermin) has been recommended [140] however, no data have been published with regard to VEGF inhibitors. The same expert panel also recommended the use of benzylamine for the prevention of radiation-induced mucositis in patients with head and neck cancer receiving radiotherapy. Stomatitis induced by mTOR inhibitors appears to be different since it involves immune mechanisms. The management might therefore be different, and corticosteroids might be helpful [127].

Treatment of stomatitis may also include mouthwashes with doxycline and/or sulrafat dissolved in water [143]. Patients who complain of inflammatory lesions may benefit from local triamcinolonacetonide. As the management of stomatitis can prove challenging, changes in treatment schedules might be considered. Several authors have reported on different modified sunitinib schedules: e.g. from 4 weeks on/2 weeks off to 2 weeks on/1 week off. While such schedules may help to prevent side-effects such as stomatitis, no changes in efficacy were observed [144–146].

5.8. Gastrointestinal perforation

5.8.1. Mechanism and clinical presentation
Gastrointestinal perforations have been rarely reported in patients with renal cell carcinoma [7]. VEGF has been shown to be highly important for the integrity of the intestinal mucosa. Vasoactive agents such as prostaglandins and NO, which are critical for mucosal defence mechanisms, are activated by VEGF [147]. Thus, VEGF has been considered a survival factor
for endothelial and epithelial cells in the intestines [148]. VEGF inhibition on capillary beds of intestinal villi may directly contribute to perforation by inducing the regression of normal blood vessels [100,149]. The occurrence of gastrointestinal perforations with VEGF inhibitors has been linked to the presence of bowel pathologies [148]. Diffuse abdominal carcinomatosis is associated with a risk of bowel obstruction, increased pressure on weakened bowel areas and microperforations [150]. Other risk factors include ulcer, bowel tumour necrosis, diverticulosis, colitis and prior abdominal or pelvic radiotherapy [151] (Gentech Inc., Avastin prescribing information, June 2006). Finally, a reduction in blood flow to the splanchnic vasculature by thrombosis or vasoconstriction may further increase the risk of bowel infarction and perforation [152]. Presentation of gastrointestinal perforation during VEGF inhibitor treatment varies in type and severity, from free air on the abdominal x-ray which resolves without treatment to colonic perforation with abdominal abscess and fatal outcome. 5.8.2. Management Patients with risk factors should be carefully monitored for clinical signs of perforation, such as abdominal pain, obstruction, fever, vomiting and leucocytosis [149]. In patients under suspicion of an increased risk of gastrointestinal perforation frequent radiographic evaluations for free peritoneal air, extraluminal contrast and abscess formation may be reasonable [151]. Physicians should also be aware of potential risks associated with co-medications such as non-steroidal anti-inflammatory drugs (NSAIDS). These increase the ratio of endostatin to VEGF and may further contribute to the occurrence of gastrointestinal perforations [153]. In patients who experience gastrointestinal perforation with VEGF inhibitors, treatment discontinuation has mostly been recommended.

| Table 3 – Toxicity as a biomarker for outcome. |
|-----------------------------------------------|
| **Agent**          | **Side-effect** | **Correlation with outcome** |
| Bevacizumab [196] | Hypertension >2 | DCR: 91% versus 48% and TTP: 8.1 versus 4.2 |
| Bevacizumab + interferon [8] | Hypertension >2 | RR: 13 versus 9; OS: 41.6 versus 16.2 |
| Sunitinib [14]    | Hypertension SBP >140, DBP >90 | RR: systolic: 55 versus 10; diastolic: 57 versus 25% |
| Sorafenib [197]   | Hypertension all | Shrinkage: 90 versus 33 |
| Axitinib [198]    | Diastol BP      | PFS: 10.3 versus 3.6 |
| Sunitinib [16]    | Hypothyroidism  | OS: 18.2 versus 6.6 |
| Sunitinib [199]   | Hypothyroidism  | PFS: 575 versus 481 days |
| Sunitinib [200]   | Hypothyroidism  | PFS: 8.55 versus 7.03 mo |
| Sunitinib + sorafenib [15] | Hypothyroidism | PFS: 17 versus 10.8; OS: nr versus 13.9 |
| SUN [14]          | Hypertension    | ORR: 54.8 versus 8.7% |
|                   |                 | PFS: 12.5 versus 3.8; OS: 30.9 versus 7.2 |

DCR, disease control rate; TTP, time to progression; RR, response rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure; PFS, progression-free survival; OS, overall survival; ORR, objective response rate.

Fig. 1 – Female patient after 3 months on axitinib (no response, no hypertension) and after dose escalation with onset of hypertension.
expressed on thyroid cells and endothelial cells of the thyroid gland which are also able to synthesise VEGF [58,154–160]. Thus, VEGF inhibitors may induce capillary regression in the thyroid [64,100], leading to the destruction of normal thyroid cells. In addition, sunitinib was shown to induce hypothyroidism by inhibiting iodine uptake [161] and peroxidase activity [162]. It remains unclear whether off-target(s) inhibition may also contribute to hypothyroidism. Multikinase inhibitors such as sunitinib were shown to strongly inhibit RET/PTC signalling, thus being potentially beneficial in the management of thyroid cancer.

5.9.2. Management

Patients treated with VEGF inhibitors should be monitored for hypothyroidism before and at regular intervals during treatment. Both clinically overt and subclinical hypothyroidism may occur. According to the clinical practice guidelines for hypothyroidism in adults [163], the standard treatment is replacement with L-thyroxine in patients with persistent TSH levels >10 mIU/L. In patients with subclinical hypothyroidism (defined as TSH <10 mIU/L), 92% would be considered for hormone replacement. These guidelines have been established to prevent the long-term damage caused by hypothyroidism in otherwise healthy patients. How relevant are these recommendations in patients with mRCC, and what are the clinical implications for the management of TKI-induced hypothyroidism? This is particularly of interest since several authors have reported on an antitumour effect of hypothyroidism. Hypothyroidism was shown to inhibit tumour cell proliferation in various cancer cells and animal models [164–167]. Moreover, hypothyroidism was shown to inhibit neoangiogenesis and to improve outcome in patients with head and neck cancer [168,169]. Thus, the question arises as to whether we should tolerate TKI-induced hypothyroidism to some extent. Physicians need to be aware that hypothyroidism has considerable effects on cardiac function, including impaired relaxation and ventricular filling, increase in peripheral vascular resistance and increased diastolic blood pressure as well as reduced ejec-
tion at exercise [170]. Therefore, hormone replacement appears to be mandatory in the majority of patients. In this context it is important to note that triiodothyronine (T3) is the relevant hormone for the cardiac myocyte. Interestingly, T3 supplementation was shown to be 50 times less proliferative and less pro-angiogenic than T4, the ‘bad guy’ among thyroid hormones [171]. An advantage of T3 replacement would also be that it reduces T4 levels; however, T3 replacement is difficult in clinical practice due to the short half-life of available formulations. This problem could potentially be solved by the use of a combination of T3 and T4. It has been stated recently that combined T3 and T4 replacement may represent a more personalised approach to treat hypothyroidism [172].

5.10. Hand–foot syndrome

5.10.1. Presentation and mechanism

HFS has been reported to occur between days 14 and 28 of VEGF inhibitor treatment [173]. According to the Common Terminology Criteria for Adverse Events (CTCAE Version 4.0, 2009), patients with grade 1 HFS present with minimal skin changes or dermatitis (erythema, oedema or hyperkeratosis) without pain. In contrast, patients with grade 2 HFS complain of painful skin changes (peeling, blisters, bleeding, oedema and hyperkeratosis) that may limit activities of daily living. Finally, grade 3 HFS has been defined as the presence of severe skin changes associated with severe pain and limited self-care.

Several histopathological changes have been described by Yang and colleagues [174]. The most common include intracytoplasmic eosinophilic bodies reflecting keratinocyte damage, keratinocyte vacuolar degeneration and confluent keratinocyte necrosis associated with intraepidermal cleavage. In addition, an accelerated epidermal cell replication and increased keratinocyte proliferation has been described by the authors. So far, the exact mechanism of HFS with multikinase inhibitors has not been elucidated. The severity of clinical presentation appears to be correlated with drug exposure. Discussed mechanisms include: (1) an increased drug concentration in the capillaries at the papillary dermis, (2) interference by VEGF–PDGFR inhibition associated with pericyte-mediated endothelial survival mechanisms, leading to damage of the capillary endothelium in hands and feet [82], (3) an impaired vascular repair leading to keratinocyte apoptosis and inflammation and (4) a direct effect of the drug in eccrine sweat glands.

5.10.2. Management

The management of HFS in patients treated with VEGF inhibitors has been reviewed by Anderson and colleagues [175]. Prophylactic measures include pedicure before treatment to remove hyperkeratosis, emollients, topical exfoliating products (urea-based and salicylic-acid-based), protection of pressure-sensitive areas (e.g. shoes with soft insoles) and perhaps systemic administration of pyridoxine, glucocorticosteroids and cycloogygease-2 inhibitors. The authors also highlight the importance of frequent and early collaborations between oncologists and dermatologists. Dose reductions and treatment interruptions may be temporarily required. The authors recommend a dose reduction at first occurrence of grade 2 until HFS resolves to grade 0–1 and to increase the dose afterwards; if no improvement to grade 0–1 occurs, treatment interruption for 7 days may be necessary. The dose may then be escalated depending on the HFS grade. In the case of grade 3 HFS, recommendations regarding dosing include the interruption of TKI treatment for 7 days (until toxicity resolves to grade 0–1) and to resume treatment at a reduced dose. If toxicity is maintained at grade 0–1 at reduced dose, dose escalation may be recommended. In the case of recurrent grade 3 HFS, treatment should be resumed at a reduced dose after recovery without further dose escalations. According to the authors, combinations of cortisone creams and topical antibi-
otics might be recommended in cases of severe HFS. These recommendations have been made for patients treated with sorafenib. Although they may also apply to pa-
tients with other VEGFR–TKIs, individual modifications according to the clinical presentation, the type of drug and the drug schedule may be reasonable.
5.11. Myelotoxicity

5.11.1. Mechanisms
Myelotoxicity of tyrosine kinase inhibitors has been linked to their ability to inhibit various targets. (1) They inhibit KIT signalling: KIT receptors are expressed on haematopoietic progenitor cells and are involved in their growth and differentiation. Sunitinib was shown to inhibit phosphorylation of the KIT receptor and cell proliferation [176]. (2) VEGF inhibition may also account for myelotoxicity. Gerber and colleagues [177] described a regulatory loop by which VEGF controls survival of haematopoietic stem cells. Interestingly, ligands selective for VEGF and VEGFR-2 as well as VEGFR-1 agonists were shown to rescue survival of VEGF-deficient haematopoietic stem cells. Moreover, VEGF was shown to be involved in the formation of myeloid and erythroid colonies from progenitor cells [178]. (3) Inhibition of FLT-3 on haematopoietic stem cells and PDGFR signalling has also been linked to myelotoxicity [179,180]. (4) Finally, it has been suggested that thrombocytopenia might be the result of hypertension [181] or may be caused by drug-induced immune thrombocytopenia [182].

5.11.2. Management
In caucasian populations, myelotoxicity is seldom a dose-limiting toxicity. The case of grade 2 neutropenia or thrombocytopenia, dose adjustments are rarely necessary. The occurrence of grade ≥3 myelotoxicity has been reported to occur more frequently in Asian patients [183]. In the case of grade 3 neutropenia or thrombocytopenia temporary treatment interruptions may be required. In the case of sunitinib, dose modifications may depend on the day on which grade 3 myelotoxicity is observed. If observed on day 28 of treatment, prior to the 2-week rest, patients may not necessarily require dose reduction in the next course because neutropenia and thrombocytopenia are usually short-lived and tend to resolve during the 2 weeks off treatment; blood cell counts should be repeated on day 1 of the next course, and if neutrophils and thrombocytes return to normal levels, careful continuation at the same dose level might be possible [107]. Blood cell counts should be obtained every 2 weeks, and in the case of repeated grade 3 myelotoxicity, treatment should be withheld for a few days until toxicity is grade 2 or less. In the case of recurring grade 3 myelotoxicity, dose reduction should be recommended after recovery [184].

6. Toxicities as biomarkers for successful outcome

Several retrospective studies have identified specific side-effects to be strongly associated with outcome. Table 3 summarises these findings. The most common side-effect that has been associated with outcome is hypertension. Additional toxicities that were shown to correlate with the outcome are myelotoxicity [185,186], HFS [186] and fatigue/asthenia [187]. What is the biological basis for this correlation? The toxicity may reflect that (1) the mechanism of action may be appropriate in the individual patient, (2) the chosen drug has a high selectivity and adequate potency to hit the target, (3) the tumour is dependent on the inhibited pathway and (4) the drug exposure is appropriate; this may also be influenced by the presence or absence of specific single-nucleotide polymorphisms that influence pharmacokinetic and pharmacodynamic processes [188,189].

The potential association of toxicities and outcome has several clinical implications and raises three major questions. (1) Should we treat the toxicity, or would this impair the outcome? In this context, correction of hypertension has been well studied. While the occurrence of hypertension appears to be predictive, treating hypertension does not appear to impair the outcome. In a retrospective analysis on hypertension as a predictive factor for outcome with sunitinib treatment, Szmit and colleagues [190] reported that patients who required at least three antihypertensive agents had the longest PFS. Thus, managing hypertension is not only mandatory for the patient’s safety, but it also does not appear to affect the outcome. These findings may, however, vary depending on the toxicity observed. As hypothyroidism was shown to be associated with the inhibition of angiogenesis [168,169] and cell proliferation [164], maintaining a state of (preferably) T4-hypothyroidism may to some extent be beneficial for the outcome. In this context, TSH levels above the upper limit of normal and below the threshold for cardiac impairments (>10 mmol/L) may be acceptable. (2) Should we adjust the dose until toxicity is observed (treating according to toxicity)? In the axitinib dose-titration trial, patients with dose titration and those who did not require dose titration as assessed by the occurrence of hypertension had a better outcome when compared to patients without dose titration [19]. Fig. 1 shows the computed tomography (CT) scans of a female mRCC-patient who did not experience either hypertension (or other dose-limiting toxicities) or remission with axitinib 5 mg bid. Only upon dose adjustment to 7 mg bid did the patient develop hypertension and a reduction in the size of metastasis. These findings suggest that we may consider a potential benefit of the ‘treat to toxicity’ approach. Naturally, such strategies should only be considered in the absence of other dose-limiting toxicities and require careful monitoring. (3) What is the role of agents given to manage the toxicity? Do these agents modify the outcome? We cannot rule out that agents given against the toxicity may have additional benefits against tumour progression. For instance, some antihypertensive agents were shown to exert interesting antitumour properties. Beta-blockers, for example, were shown to induce apoptosis in endothelial cells [191] and have been established as standard of care for infantile haemangiomias [192]. Moreover, several reports have demonstrated that angiotensin II stimulates growth and migration of cancer cell lines and induces angiogenesis through up-regulation of VEGF; interestingly, this effect can be inhibited by angiotensin-receptor blockers (ARBs) [193]. Losartan, an ARB, was shown to stimulate pro-apoptotic signalling pathways in various tumour types [194,195]. Finally, calcium-channel blockers have been shown to reduce the proliferation and migration of glioma cells [196].
7. Conclusions

VEGF inhibitors have substantially improved the outcome of patients with metastatic renal-cell carcinoma. Incidence and severity of side-effects may vary between agents and depend on the mode of action of the chosen drug as well as on individual patient-related factors. Physicians need to be aware of both patient- and agent-related risks that may occur during treatment in order to choose the best individual treatment and maintain the patient’s safety and quality of life. It should be considered that the majority of side-effects are manageable with proactive supportive measures and close monitoring of the patient. Dose reductions, treatment interruptions and discontinuation should be avoided whenever possible.

Conflict of interest

Honoraria for lectures or advisory role from Pfizer, Bayer, Roche, Astellas, GSK, Novartis; Research grants from GSK, Pfizer, Novartis.

REFERENCES

[1] Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.
[2] Motzer RJ, Hutson TE, Reeves J, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. 2012 ESMO Congress; 2012.
[3] Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
[4] Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.
[5] Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931–9.
[6] Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–8.
[7] Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–11.
[8] Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137–43.
[9] Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012;30:1678–85.
[10] Motzer RJ et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012;30(Suppl.) [abstr. 4501].
[11] Houk BE, Bello CI, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357–71.
[12] Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–34.
[13] Bukowski RM, Kabbabin RV, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536–41.
[14] Rini B. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with renal cell carcinoma (mRCC) treated with sunitinib. ASCO GU 2010 [abstr. 312].
[15] Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with metastatic renal cell carcinoma: blessing or curse? Cancer 2011;117:534–44.
[16] Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99:448–54.
[17] Makita N, Miyakawa M, Fujita T, Iini T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010;20:323–6.
[18] Amato R, Zhai J, Willis J, Saxena S, DeFoe M. A phase II trial of intradose escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:153–8.
[19] Rini BI, Gruenwald V, Fishman MN, et al. Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): unblinded results from a randomized phase II study. J Clin Oncol 2013;31(Suppl. 6) [abstr. LBA349].
[20] Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998;12:369–77.
[21] Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153–60.
[22] Miaskowski C, Dodd M, Lee K, et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manage 2010;40:531–44.
[23] Aouizerat BE, Dodd M, Lee K, et al. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs 2009;11:27–41.
[24] Rausch SM, Clark MM, Patten C, et al. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer 2010;116:4053–13.
[25] Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing psychological stress on circulating inflammatory factors in oncology patients and their family caregivers. J Pain Symptom Manage 2007;34:427–39.
[26] Jacobsen PB. Progress toward guidelines for the management of fatigue. Biol Res Nurs 2009;11:27–41.
[27] Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007;21:901–12.
[28] Donovan KA, Small BJ, Andrykowski MA, Munster P, Jacobsen PB. Utility of a cognitive-behavioral model to
predict fatigue following breast cancer treatment. Health Psychol 2007;26:464–72.

[29] Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006;130:103–24.

[30] Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904–12.

[31] Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010;10:1019–35.

[32] Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988;12:123–37.

[33] Dantzker R, Kelley KW. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci 1989;44(26):1995–2008.

[34] Dantzker R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001;15:7–24.

[35] Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 – from the Groupe Francais d’Immunotherapie. J Clin Oncol 2004;22:2371–8.

[36] Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cystic anticancer vaccines. Semin Immunol 2010;22:113–24.

[37] Wang XS, Shi Q, Williams LA, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010;24:968–74.

[38] Louwerens M, Appelhof BC, Verloop H, et al. Fatigue and hypothyroidism. Eur J Endocrinol 2012;167:809–15.

[39] Aubier M, Murciano D, Lecocguic Y, et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med 1985;313:420–4.

[40] Zazko JF, Troche G, Ruel P, Maintenant J. High incidence of fatigue and thyrotropin-releasing hormone. Curr Aging Sci 2012;5:195–202.

[41] Richter EA, Derave W, Wojtaszewski JF. Glucose, exercise and insulin: emerging concepts. J Physiol 2001;535:313–22.

[42] Fabian MA, Biggs III WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329–36.

[43] Billemont B, Medioni J, Taillade L, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008;99:1380–2.

[44] Yavuzsen T, Davis MP, Ranganath M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335–45.

[45] Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17:2793–800.

[46] Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffer TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652–8.

[47] Machnik A, Neuhofer W, Jantsch J, et al. Macrophages subjugate the immune system in the cancer microenvironment. Cancer Treat Res 2006;130:5–24.

[48] Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997;420:2371–8.

[49] Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35–52.

[50] Baffert F, Le T, Sennino B, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014–9.
[67] Schmidinger M, Bergler-Klein J. Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. Int J Urol 2012;19:796–804.

[68] Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117–23.

[69] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52.

[70] Mancia G, De BG, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462–536.

[71] Blanco S, Bonet J, Lopez D, Casas I, Romero R. ACE inhibitors improve nphrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl 2005;93:S10–4.

[72] Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase 1-NO pathway. Hypertens Res 2005;28:147–53.

[73] Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439–48.

[74] Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–16.

[75] Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65:2003–17.

[76] Garovic VD, Wagner SJ, Petrovic LM, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007;22:1136–43.

[77] Paolotti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Hypertens 2005;18:320–7.

[78] Perkovic V, Verdon C, Ninomiya T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008;5:e207.

[79] Peterson JC, Adler S, Burkart JM, et al. Blood pressure and meta-analysis. PLoS Med 2008;5:e207.

[80] Fan L, Iseki S. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 1998;61:17–28.

[81] Iervasi G, Pingitore A, Landi P, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003;107:708–13.

[82] Taddei S, Caraccio N, Iskandrian A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Evidence from a magnetic resonance imaging study. J Am Coll Cardiol 2005;45:439–45.

[83] Faber J, Petersen L, Wünberg N, Schiffer S, Mehlson J. Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. Thyroid 2002;12:319–24.

[84] Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997;7:411–14.

[85] Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003;88:3731–7.

[86] Schmidinger M, Bergler-Klein J. Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. Int J Urol 2012;19:796–804.

[87] Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332–44.

[88] Ayach BB, Yoshimitsu M, Dawood F, et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A 2006;103:2304–9.

[89] Fazel S, Gimenez-Roldan T, Sandoval A, et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006;116:1865–77.

[90] Wang CH, Anderson N, Li SH, et al. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res 2006;99:617–25.

[91] Schmidinger M, Larkin J, Ravaud A. Experience with sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Am Coll Cardiol 2005;46:2116–24.

[92] Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332–44.
[105] Sanders KM, Koh SD, Ward SM. Intestinal cells of cajal as pacemakers in the gastrointestinal tract. Annu Rev Physiol 2006;68:307–43.

[106] Deininger MW. Cytogenetic studies in patients on imatinib. Semin Hematol 2003;40(2 Suppl. 2):50–5.

[107] Schmider M, Bellmunt J. Phlethora of agents, phlethora of targets, phlethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010;36:416–24.

[108] Becker B, Kuhn U, Hardewig-Budny B. Double-blind, randomized evaluation of clinical efficacy and tolerability of an apple-pectin-chamomile extract in children with unexplained diarrhea. Arzneimittelforschung 2006;56:387–93.

[109] Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer. a randomised study. Br J Cancer 2007;97:1028–34.

[110] Von Bultzingslowen I, Ryden M, Arvidsson E, Blomqvist L, et al. Targets for TNF-alpha-induced diarrhea. J Clin Invest 1997;100:2641–7.

[111] Wood SC. Biological oxygenation: circulation, respiration, and metabolism. Science 1986;234:491–2.

[112] Placidi E, Marciani L, Hoad CL, et al. The effects of irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a manntitol model of secretory diarrhoea. Aliment Pharmacol Ther 2012;36:64–73.

[113] Dueno MI, Bai JC, Santangelo WC, Krejs GJ. Effect of loperamide on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 2005;50:1092–6.

[114] Lenfers BH, Loeffler TM, Droge CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11)-induced diarrhea. Ann Oncol 1999;10:1251–3.

[115] Dueo MJ, Bai JC, Santangelo WC, Krejs GJ. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987;32(10):1092–6.

[116] Zachariah B, Gwede CK, James J, et al. Occurrence of gastrointestinal side effects in patients with advanced colorectal cancer. Oncology 2005;68:326–32.

[117] Karthaus M, Ballo H, Abenhardt W, et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005;68:326–32.

[118] Bowen JM, Stringer AM, Gibson RJ, et al. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007;6:1449–54.

[119] Arcavi L, Shahar A. Drug related taste disturbances: a diagnostic and therapeutic protocol. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:320–6.

[120] Frei III E, Levin RH, Bodey GP, Morse EE, Freireich EJ. The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.02, 2009.

[121] Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1(2 Suppl.):541–54.

[122] Steinberg EM. Neural-immune interactions in health and disease. J Clin Invest 1997;100:2641–7.
[143] Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008;6(Suppl. 1):S1–21.

[144] Buti S, Donini M, Lazzarelli S, Passalacqua R. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis. Acta Biomed 2012;83:88–94.

[145] Neri B, Vannini A, Brugia M, et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2013;20:476–83.

[146] Sato K, Terada K, Sugiyama T, et al. Frequent overexpression of vascular endothelial growth factor gene and protein: strong expression in papillary thyroid carcinoma in children and young adults. J Clin Endocrinol Metab 2001;86:1596–601.

[147] Mishkin SY, Pollack R, Yalovsky MA, Morris HP, Mishkin S. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res 1981;41:3040–5.

[148] Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:1041–6.

[149] Biondi B, Wartofsky L. Combination treatment with T4 and radioiodine for the management of hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2005;15:1–5.

[150] Anderson R, Jatoi A, Robert C, Spatz A, et al. Cutaneous side-effects of multitargeted kinase inhibitors and blocking antibodies. Lancet Oncol 2007;8(Suppl. 1):S12–5.

[151] Robert C, Spatz A, et al. Cutaneous side-effects of multitargeted kinase inhibitors and blocking antibodies. Lancet Oncol 2007;8(Suppl. 1):S12–5.

[152] Yang CH, Lin WC, Chuang CK, et al. Hand–foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;159:592–6.

[153] Anderson R, Jatoi A, Robert C, Spatz A, et al. Cutaneous side-effects of multitargeted kinase inhibitors and blocking antibodies. Lancet Oncol 2007;8(Suppl. 1):S12–5.

[154] Brandt J, Bridell RA, Sutow WR, Leemhuis TB, Hoffman R. Role of c-kit ligand in the expansion of human hematopoietic progenitor cells. Blood 1999;92:634–41.

[155] Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954–8.

[156] Manovola D, Cocco P, Vannucci G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531–4.
pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37.

[180] Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherriington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471–8.

[181] Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745–7.

[182] Trinkaus M, Trudeau M, Callum J. Drug-induced immune thrombocytopenic purpura secondary to sunitinib. Curr Oncol 2008;15:152–4.

[183] Yoo C, Kim JR, Lee JI, et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn Clin Oncol 2010;40:980–5.

[184] Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010;28:856–64.

[185] Donskov F, et al. Neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients with metastatic renal cell carcinoma (mRCC). Poster presentation at the European Multidisciplinary Cancer Congress; 2011 [abstr. 1144].

[186] Puzanov I, et al. Evaluation of hand–foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumour (GIST). Poster presentation at the European Multidisciplinary Cancer Congress; 2011 [abstr. 1144].

[187] Davis Meal. Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma. Poster presentation at the European Multidisciplinary Cancer Congress; 2011 [abstr. 1139].

[188] Kim JJ, Vaziri SA, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012;118:1946–54.

[189] Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011;12:1143–50.

[190] Szmit S, Langiewicz P, Znierek J, et al. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 2012;35:18–25.

[191] Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298–304.

[192] Menezes MD, McCarter R, Greene EA, Bauman NM. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol 2011;120:686–95.

[193] Wasa J, Sugitana H, Kozawa E, Kohyama K, Yamada K, Taguchi O. The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model. Anticancer Res 2011;31:123–7.

[194] Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA. Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 2010;39:581–94.

[195] Molteni A, Heffelfinger S, Moulder JE, Uhal B, Castellani WJ. Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem 2006;6:451–60.

[196] Santoni G, Santoni M, Nabissi M. Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy. Br J Pharmacol 2012;166:1244–6.

[197] Bono P, Elving H, Utriaien T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393–4.

[198] Nozawa M, Matsumura N, Yasuda M, Okuda Y, Uemura H. Activity of retreatment with sorafenib for metastatic renal cell carcinoma. In: ASCO Genitourinary Cancers Symposium, February 17–19, Orlando, Florida, 2011 [abstr. 404].

[199] Rixe O. Diastolic blood pressure (DBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 2009;27(Suppl.):15s [abstr. 5045].

[200] Feal Bladou. Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): a prospective observational analysis. J Clin Oncol 2010;28(Suppl.):13 [abstr. e15013].

[201] Baldazzi V, Tassi R, Lapini A, et al. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2012 Sep;30(5):704–10.